Plus Therapeutics Posts Q2 Profit Jump
Plus Therapeutics (NASDAQ:PSTV), a clinical-stage biotech focused on radiotherapeutics and diagnostics for central nervous system cancers, reported its second quarter 2025 results on August 14, 2025. The company posted a significant turnaround in GAAP net income, moving from a $(2.9) million loss in Q2 2024 to a $5.2 million profit, though this was driven primarily by a nonrecurring $6.5 million fair value adjustment related to derivative instruments. GAAP revenue grew to $1.4 million compared to $1.3 million in the same quarter of 2024, just below the $1.49 million GAAP consensus estimate. GAAP earnings per share was $0.02, beating expectations by $0.11 (GAAP EPS). GAAP operating losses narrowed compared to Q2 2024. While overall results reflected cost discipline and pipeline progress, the core business remains reliant on grant revenue, and product sales have yet to begin.
Source: Analyst estimates for the quarter provided by FactSet.
Plus Therapeutics develops radiotherapeutic medicines and diagnostic assays aimed at treating cancers that affect the central nervous system, such as glioblastoma and leptomeningeal metastases. The company's primary asset is REYOBIQ, a patented radiotherapy delivered directly into the central nervous system. The pipeline also includes the CNSide diagnostic platform designed to deliver more sensitive detection of tumor cells in spinal fluid.
Source Fool.com
